Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Codexis, Inc. stock logo
CDXS
Codexis
$2.55
+6.3%
$2.40
$1.90
$6.08
$211.26M2.56692,959 shs995,063 shs
Dominari Holdings Inc. stock logo
DOMH
Dominari
$4.68
+1.7%
$4.63
$0.83
$13.58
$68.53M0.591.25 million shs237,291 shs
Vanda Pharmaceuticals Inc. stock logo
VNDA
Vanda Pharmaceuticals
$4.33
$4.34
$3.81
$6.75
$255.18M0.69715,378 shs264,563 shs
XOMA Co. stock logo
XOMA
XOMA
$24.92
+0.3%
$22.67
$18.35
$35.00
$298.22M0.8930,822 shs21,233 shs
Elon Musk's Next Move Cover

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Codexis, Inc. stock logo
CDXS
Codexis
+6.25%+4.08%+12.83%-38.70%-19.56%
Dominari Holdings Inc. stock logo
DOMH
Dominari
+1.74%-11.03%-2.30%-43.75%+114.68%
Vanda Pharmaceuticals Inc. stock logo
VNDA
Vanda Pharmaceuticals
0.00%-2.48%+1.88%-8.07%-17.21%
XOMA Co. stock logo
XOMA
XOMA
+0.28%-6.32%+3.23%+8.68%+0.04%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Codexis, Inc. stock logo
CDXS
Codexis
3.2478 of 5 stars
3.31.00.02.52.51.70.6
Dominari Holdings Inc. stock logo
DOMH
Dominari
1.5534 of 5 stars
0.04.00.00.03.12.50.6
Vanda Pharmaceuticals Inc. stock logo
VNDA
Vanda Pharmaceuticals
4.6532 of 5 stars
3.82.00.04.24.13.31.3
XOMA Co. stock logo
XOMA
XOMA
4.0889 of 5 stars
3.52.00.03.03.23.30.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Codexis, Inc. stock logo
CDXS
Codexis
2.67
Moderate Buy$8.00213.73% Upside
Dominari Holdings Inc. stock logo
DOMH
Dominari
0.00
N/AN/AN/A
Vanda Pharmaceuticals Inc. stock logo
VNDA
Vanda Pharmaceuticals
3.50
Strong Buy$16.50281.06% Upside
XOMA Co. stock logo
XOMA
XOMA
3.00
Buy$69.50178.89% Upside

Current Analyst Ratings Breakdown

Latest DOMH, XOMA, VNDA, and CDXS Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/14/2025
Vanda Pharmaceuticals Inc. stock logo
VNDA
Vanda Pharmaceuticals
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight$13.00
5/13/2025
Vanda Pharmaceuticals Inc. stock logo
VNDA
Vanda Pharmaceuticals
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
5/7/2025
Vanda Pharmaceuticals Inc. stock logo
VNDA
Vanda Pharmaceuticals
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$20.00 ➝ $20.00
4/17/2025
XOMA Co. stock logo
XOMA
XOMA
Benchmark
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$35.00
4/1/2025
Vanda Pharmaceuticals Inc. stock logo
VNDA
Vanda Pharmaceuticals
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$20.00 ➝ $20.00
3/28/2025
XOMA Co. stock logo
XOMA
XOMA
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$104.00 ➝ $104.00
3/19/2025
XOMA Co. stock logo
XOMA
XOMA
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$104.00 ➝ $104.00
(Data available from 5/28/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Codexis, Inc. stock logo
CDXS
Codexis
$49.82M4.24N/AN/A$1.24 per share2.06
Dominari Holdings Inc. stock logo
DOMH
Dominari
$24.89M2.75N/AN/A$9.90 per share0.47
Vanda Pharmaceuticals Inc. stock logo
VNDA
Vanda Pharmaceuticals
$201.35M1.27N/AN/A$9.23 per share0.47
XOMA Co. stock logo
XOMA
XOMA
$13.05M22.86N/AN/A$7.72 per share3.23
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Codexis, Inc. stock logo
CDXS
Codexis
-$76.24M-$0.99N/AN/AN/A-96.35%-71.56%-38.00%8/14/2025 (Estimated)
Dominari Holdings Inc. stock logo
DOMH
Dominari
-$22.88M-$4.50N/AN/A-180.22%-32.89%-29.47%8/6/2025 (Estimated)
Vanda Pharmaceuticals Inc. stock logo
VNDA
Vanda Pharmaceuticals
-$18.90M-$0.75N/AN/AN/A-9.51%-3.49%-2.90%7/30/2025 (Estimated)
XOMA Co. stock logo
XOMA
XOMA
-$40.83M-$1.15N/AN/AN/A-151.34%-24.95%-9.64%8/12/2025 (Estimated)

Latest DOMH, XOMA, VNDA, and CDXS Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/14/2025Q1 2025
Codexis, Inc. stock logo
CDXS
Codexis
-$0.20-$0.25-$0.05-$0.25$10.38 million$7.54 million
5/13/2025Q1 2025
XOMA Co. stock logo
XOMA
XOMA
-$0.26$0.06+$0.32$0.06$6.75 million$15.91 million
5/7/2025Q1 2025
Vanda Pharmaceuticals Inc. stock logo
VNDA
Vanda Pharmaceuticals
-$0.55-$0.50+$0.05-$0.50$45.13 million$50.04 million
4/15/2025Q4 2024
Dominari Holdings Inc. stock logo
DOMH
Dominari
N/A$0.20N/A$0.20N/A$6.56 million
3/17/2025Q4 2024
XOMA Co. stock logo
XOMA
XOMA
-$0.29-$0.46-$0.17-$0.46$8.75 million$8.70 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Codexis, Inc. stock logo
CDXS
Codexis
N/AN/AN/AN/AN/A
Dominari Holdings Inc. stock logo
DOMH
Dominari
N/AN/AN/AN/AN/A
Vanda Pharmaceuticals Inc. stock logo
VNDA
Vanda Pharmaceuticals
N/AN/AN/AN/AN/A
XOMA Co. stock logo
XOMA
XOMA
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Codexis, Inc. stock logo
CDXS
Codexis
0.39
3.21
3.15
Dominari Holdings Inc. stock logo
DOMH
Dominari
N/A
10.25
10.25
Vanda Pharmaceuticals Inc. stock logo
VNDA
Vanda Pharmaceuticals
N/A
4.39
4.37
XOMA Co. stock logo
XOMA
XOMA
1.28
7.52
7.52

Institutional Ownership

CompanyInstitutional Ownership
Codexis, Inc. stock logo
CDXS
Codexis
78.54%
Dominari Holdings Inc. stock logo
DOMH
Dominari
42.48%
Vanda Pharmaceuticals Inc. stock logo
VNDA
Vanda Pharmaceuticals
88.14%
XOMA Co. stock logo
XOMA
XOMA
95.92%

Insider Ownership

CompanyInsider Ownership
Codexis, Inc. stock logo
CDXS
Codexis
2.10%
Dominari Holdings Inc. stock logo
DOMH
Dominari
32.98%
Vanda Pharmaceuticals Inc. stock logo
VNDA
Vanda Pharmaceuticals
10.00%
XOMA Co. stock logo
XOMA
XOMA
9.10%
CompanyEmployeesShares OutstandingFree FloatOptionable
Codexis, Inc. stock logo
CDXS
Codexis
25082.85 million79.67 millionOptionable
Dominari Holdings Inc. stock logo
DOMH
Dominari
414.64 million4.01 millionNot Optionable
Vanda Pharmaceuticals Inc. stock logo
VNDA
Vanda Pharmaceuticals
29058.93 million53.13 millionOptionable
XOMA Co. stock logo
XOMA
XOMA
1011.97 million10.94 millionOptionable

Recent News About These Companies

XOMA Royalty Reports Strong Q1 2025 Results
XOMA Royalty: Q1 Earnings Snapshot
High Growth Tech Stocks In The US To Watch April 2025
Xoma initiated with a Buy at Benchmark

New MarketBeat Followers Over Time

Media Sentiment Over Time

Codexis stock logo

Codexis NASDAQ:CDXS

$2.55 +0.15 (+6.25%)
Closing price 05/27/2025 04:00 PM Eastern
Extended Trading
$2.48 -0.07 (-2.75%)
As of 05/27/2025 06:20 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Codexis, Inc. discovers, develops, and sells enzymes and other proteins. The company operates through two segments, Performance Enzymes and Novel Biotherapeutics. It offers biocatalyst products and services. The company also provides biocatalyst screening and protein engineering services. In addition, it offers CodeEvolver, a technology platform, which helps in developing and delivering biocatalysts that perform chemical transformations and enhance the efficiency and productivity of manufacturing processes. The company's platform is also used for molecular biology and in vitro diagnostic enzymes. It has a collaboration agreement with Nestlé Health Science to develop CDX-7108 for the treatment of exocrine pancreatic insufficiency. The company sells its products to pharmaceutical manufacturers through its direct sales and business development force in the United States and Europe. The company was incorporated in 2002 and is headquartered in Redwood City, California.

Dominari stock logo

Dominari NASDAQ:DOMH

$4.68 +0.08 (+1.74%)
As of 05/27/2025 04:00 PM Eastern

Dominari Holdings Inc., a biotechnology company, focuses on developing small-molecule anticancer therapeutics. The company's pipeline of therapeutics includes therapies for prostate cancer, pancreatic cancer, acute myeloid leukemia (AML), and acute lymphoblastic leukemia. It is developing DHA-dFdC, a pancreatic drug candidate; and KPC34, a small molecule treatment for acute myeloid leukemia and acute lymphoblastic leukemia. The company is also developing an antiviral platform that inhibits replication of viruses, including influenza virus, Ebolavirus and Marburg virus, SARS-CoV, MERS-CoV, and SARS-CoV-2. It has license agreements with the University of Texas, Silo Pharma Inc., and Wake Forest University Health Sciences. The company was formerly known as AIkido Pharma Inc. and changed its name to Dominari Holdings Inc. in December 2022. Dominari Holdings Inc. was founded in 1967 and is headquartered in New York, New York.

Vanda Pharmaceuticals stock logo

Vanda Pharmaceuticals NASDAQ:VNDA

$4.33 0.00 (0.00%)
Closing price 05/27/2025 04:00 PM Eastern
Extended Trading
$4.28 -0.05 (-1.25%)
As of 05/27/2025 05:15 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia. Its pipeline products include HETLIOZ (tasimelteon) to treat jet lag disorder, insomnia, delayed sleep phase disorder, sleep disturbances in autism spectrum disorder, and pediatric Non-24; Fanapt (iloperidone) for the treatment of bipolar I disorder and Parkinson's disease psychosis, as well as a long acting injectable (LAI) formulation to treat schizophrenia; and Tradipitant (VLY-686), a small molecule neurokinin-1 receptor (NK-1R) antagonist to treat gastroparesis, motion sickness, atopic dermatitis, and COVID-19 pneumonia. The company's pipeline products also include VTR-297, a small molecule histone deacetylase inhibitor to treat hematologic malignancies and with potential use as a treatment for various oncology indications; VQW-765, a small molecule nicotinic acetylcholine receptor partial agonist to treat performance anxiety and psychiatric disorders; VHX-896, an active metabolite of iloperidone; and antisense oligonucleotide molecules. In addition, it offers a portfolio of cystic fibrosis transmembrane conductance regulator activators and inhibitors that include VSJ-110 for the treatment of dry eye and ocular inflammation; and VPO-227 for the treatment of secretory diarrhea disorders comprising cholera. Vanda Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in Washington, the District of Columbia.

XOMA stock logo

XOMA NASDAQ:XOMA

$24.92 +0.07 (+0.28%)
Closing price 05/27/2025 04:00 PM Eastern
Extended Trading
$24.95 +0.03 (+0.12%)
As of 05/27/2025 04:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets. It has a portfolio with various assets. XOMA Corporation was incorporated in 1981 and is headquartered in Emeryville, California.